Bio-Technopark

In very close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital, a science park for life science companies and institutions has developed in the last two decades, which has now acquired both national and international significance. On an area of 55,000 m2, the park now hosts 45 companies and many academic institutions representing a healthy mix of young start-ups and global companies as well as university clinics, institutes, and research groups.

read more

Leasing

In the Bio-Technopark, it is possible to rent ultramodern laboratories, offices, and complex infrastructure for research and development purposes. The premises offered include fully-equipped laboratory facilities with communal infrastructure, and individual rental areas in different sizes and locations and with different fit-out standards. The Bio-Technopark is still being developed and gradually fitted out.

read more

Services

The Bio-Technopark promotes the transfer of knowledge and technology, as well as the foundation and building up of life science companies. In addition to advice, coaching, and support for those who are setting up and developing companies and looking for financing, its services include the organization of events that focus on networking, facilitating the exchange of ideas between specialists, and advanced training.

 

read more

News

Proteomedix appoints Helge Lubenow as new CEO

Zurich-Schlieren, Switzerland, January 10, 2020. Proteomedix, a swiss diagnostics company committed to advance prostate cancer care announced today that its board of directors has appointed Helge Lubenow as Chief Executive Officer effective January 1, 2020. Helge will succeed Ralph Schiess, co-founder of Proteomedix who is transitioning to a newly established...

read more

Molecular Partners Receives Orphan Drug Designation for MP0250 for Multiple Myeloma

Zurich-Schlieren, Switzerland, December 27, 2019. Molecular Partners AG (SIX:MOLN), a clinicalstage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, announces the receipt of Orphan Drug Designation by the US Food and Drug Administration (FDA) for its novel therapeutic, MP0250, for the treatment of Multiple Myeloma. MP0250 is...

read more

Events

  • Life Science Zurich Impact Conference: The Cause of Health
    03.02.2020
  • Bio-Technopark After Work Networking Aperitif
    04.02.2020
  • Strategies for Financing in Life Sciences
    04.02.2020